[go: up one dir, main page]

MA38146B1 - Nouveaux dérivés du benzimidazole comme antagonistes ep4 - Google Patents

Nouveaux dérivés du benzimidazole comme antagonistes ep4

Info

Publication number
MA38146B1
MA38146B1 MA38146A MA38146A MA38146B1 MA 38146 B1 MA38146 B1 MA 38146B1 MA 38146 A MA38146 A MA 38146A MA 38146 A MA38146 A MA 38146A MA 38146 B1 MA38146 B1 MA 38146B1
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
antagonists
novel benzimidazole
preparation
novel
Prior art date
Application number
MA38146A
Other languages
English (en)
Other versions
MA38146A1 (fr
Inventor
Ludwig Zorn
Laak Antonius Ter
Joachim Kuhnke
Olaf Peters
Nico Bräuer
Thorsten Blume
Jens Nagel
Stefan Kaulfuss
Gernot Langer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47325927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38146(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38146A1 publication Critical patent/MA38146A1/fr
Publication of MA38146B1 publication Critical patent/MA38146B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés du benzimidazole de la formule générale (i), des procédés pour leur préparation et leur utilisation à la préparation de produits pharmaceutiques pour le traitement d'affection et pour des indications en rapport avec le récepteur ep4.
MA38146A 2012-12-06 2013-12-03 Nouveaux dérivés du benzimidazole comme antagonistes ep4 MA38146B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195849 2012-12-06
PCT/EP2013/075309 WO2014086739A1 (fr) 2012-12-06 2013-12-03 Nouveaux dérivés du benzimidazole comme antagonistes ep4

Publications (2)

Publication Number Publication Date
MA38146A1 MA38146A1 (fr) 2018-01-31
MA38146B1 true MA38146B1 (fr) 2018-08-31

Family

ID=47325927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38146A MA38146B1 (fr) 2012-12-06 2013-12-03 Nouveaux dérivés du benzimidazole comme antagonistes ep4

Country Status (40)

Country Link
US (1) US9708311B2 (fr)
EP (1) EP2928884B1 (fr)
JP (1) JP6367822B2 (fr)
KR (1) KR20150092248A (fr)
CN (1) CN104854098B (fr)
AP (1) AP3862A (fr)
AR (1) AR093840A1 (fr)
AU (1) AU2013354226B2 (fr)
BR (1) BR112015012555B1 (fr)
CA (1) CA2893630C (fr)
CL (1) CL2015001508A1 (fr)
CR (1) CR20150296A (fr)
CU (1) CU20150056A7 (fr)
CY (1) CY1119200T1 (fr)
DK (1) DK2928884T3 (fr)
EA (1) EA028830B1 (fr)
EC (1) ECSP15022555A (fr)
ES (1) ES2637738T3 (fr)
GT (1) GT201500138A (fr)
HR (1) HRP20171200T1 (fr)
IL (1) IL239026A0 (fr)
JO (1) JO3431B1 (fr)
LT (1) LT2928884T (fr)
MA (1) MA38146B1 (fr)
ME (1) ME02950B (fr)
MX (1) MX2015007135A (fr)
MY (1) MY175272A (fr)
NI (1) NI201500077A (fr)
NZ (1) NZ707825A (fr)
PE (1) PE20151065A1 (fr)
PH (1) PH12015501289B1 (fr)
PL (1) PL2928884T3 (fr)
PT (1) PT2928884T (fr)
RS (1) RS56121B1 (fr)
SI (1) SI2928884T1 (fr)
TN (1) TN2015000250A1 (fr)
TW (1) TWI613198B (fr)
UA (1) UA115576C2 (fr)
UY (1) UY35177A (fr)
WO (1) WO2014086739A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (fr) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Preparations et therapies de substitution pour hormonotherapie naturelle combinee
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US10053454B2 (en) 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
KR20160060660A (ko) 2013-10-01 2016-05-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 친화성 크로마토그래피를 위한 및 치료제의 반감기를 연장시키기 위한 화합물
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CA2934953C (fr) * 2013-12-24 2022-09-20 Bristol-Myers Squibb Company Composes de pyrido[3,2-b]indole substitues et compositions pharmaceutiques comme agents anticancer
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CN104326937B (zh) * 2014-09-03 2016-08-24 天津市肿瘤研究所 抗肿瘤化合物及其医药用途
KR102336926B1 (ko) 2014-10-06 2021-12-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3436446B1 (fr) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
UA124708C2 (uk) 2016-09-30 2021-11-03 Вертекс Фармасьютікалз Інкорпорейтед Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора
AU2017371200B2 (en) 2016-12-09 2021-05-06 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018162562A1 (fr) * 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Utilisation d'un antagoniste d'ep4 pour le traitement de la douleur inflammatoire
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
MA49126B1 (fr) 2017-05-18 2021-10-29 Idorsia Pharmaceuticals Ltd Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
SI3625224T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituirani indolni derivati
WO2018210988A1 (fr) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
WO2018210992A1 (fr) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
KR102606188B1 (ko) 2017-08-02 2023-11-23 버텍스 파마슈티칼스 인코포레이티드 피롤리딘 화합물을 제조하기 위한 공정
WO2019038156A1 (fr) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft Utilisation d'un antagoniste d'ep4 pour le traitement de l'arthrite
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US20210300921A1 (en) * 2018-07-11 2021-09-30 Arrys Therapeutics, Inc. Ep4 inhibitors and synthesis thereof
CN113527206B (zh) * 2020-04-17 2022-12-30 上海中泽医药科技有限公司 一种苯并氮杂环类化合物、其制备方法及用途
US20230183234A1 (en) * 2020-05-04 2023-06-15 Otsuka Pharmaceutical Co., Ltd. Iap antagonist compounds and intermediates and methods for synthesizing the same
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
US12016847B2 (en) 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
KR102708701B1 (ko) * 2021-12-27 2024-09-24 에이치케이이노엔 주식회사 벤즈이미다졸 유도체의 제조방법
CN116789646B (zh) * 2023-07-12 2025-07-08 广西医科大学 咔唑-苯并咪唑偶联类化合物及其应用
TW202542134A (zh) * 2023-12-22 2025-11-01 日商Ａｇｃ股份有限公司 新穎之ep4拮抗劑

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
SI1611892T1 (sl) 2000-01-18 2010-01-29 Bayer Schering Pharma Ag Farmacevtski sestavki, ki obsegajo drospirenon
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2005533756A (ja) 2002-04-12 2005-11-10 ファイザー株式会社 Ｉｌ−６関連疾病の治療におけるｅｐ４レセプターリガンドの使用
KR20050026031A (ko) * 2002-07-31 2005-03-14 유로-셀티큐 에스.에이. 아릴 치환된 벤즈이미다졸 및 나트륨 채널 차단제로서이의 용도
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
NZ540321A (en) 2002-11-15 2007-09-28 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
US6949564B2 (en) * 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
DK1603893T3 (da) 2003-01-29 2008-09-08 Asterand Uk Ltd EP4 -Receptorantagonister
JP2006522070A (ja) 2003-04-03 2006-09-28 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール誘導体及びこれをｇａｂａａ受容体複合体をモジュレートするために使用する方法
TW200512147A (en) 2003-07-25 2005-04-01 Black Clawson Converting Machinery Inc Method and apparatus for splicing webs
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
MXPA06012172A (es) 2004-04-20 2007-01-17 Pfizer Prod Inc Combinaciones que comprenden ligandos alfa-2-delta y antagonistas del receptor ep4.
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
ATE435198T1 (de) 2004-05-04 2009-07-15 Raqualia Pharma Inc Orthosubstituierte aryl- oder heteroarylamidverbindungen
DE602005026867D1 (de) * 2005-01-19 2011-04-21 Biolipox Ab Entzündungshemmende indol-derivate
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
US7732447B2 (en) * 2006-06-22 2010-06-08 Cephalon, Inc. Fused [d]pyridazin-7-ones
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
CN101541778B (zh) 2006-08-11 2014-10-08 默克加拿大有限公司 作为ep4受体配体的噻吩甲酰胺衍生物
WO2008104055A1 (fr) 2007-02-26 2008-09-04 Merck Frosst Canada Ltd. Dérivés d'indole et indoline cyclopropyl amide comme antagonistes du récepteur ep4
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2460787A1 (fr) 2007-07-03 2012-06-06 Astellas Pharma Inc. Composés d'amide et leur utilidsation comme anagonistes de la PGE2.
AU2008284303A1 (en) 2007-08-09 2009-02-12 Merck & Co., Inc. Process for making thiophene carboxamide derivative
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
WO2010117639A2 (fr) 2009-03-31 2010-10-14 The Texas A&M University System Inhibition des récepteurs de la prostaglandine e2 pour le traitement d'une endométriose
WO2010124097A2 (fr) 2009-04-22 2010-10-28 Paratek Pharmaceuticals, Inc. Composés modulateurs de facteur de transcription et leurs procédés d'utilisation
US9457084B2 (en) * 2010-02-22 2016-10-04 Raqualia Pharma Inc. Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物

Also Published As

Publication number Publication date
BR112015012555A2 (pt) 2017-07-11
ME02950B (fr) 2018-07-20
CY1119200T1 (el) 2018-02-14
JP2016501241A (ja) 2016-01-18
MX2015007135A (es) 2016-02-05
ECSP15022555A (es) 2016-01-29
TWI613198B (zh) 2018-02-01
AU2013354226A1 (en) 2015-06-18
DK2928884T3 (en) 2017-09-11
WO2014086739A1 (fr) 2014-06-12
PT2928884T (pt) 2017-08-25
EA028830B1 (ru) 2018-01-31
AP2015008463A0 (en) 2015-05-31
CN104854098B (zh) 2018-01-09
PE20151065A1 (es) 2015-08-19
CA2893630C (fr) 2021-02-23
CL2015001508A1 (es) 2015-07-24
EP2928884B1 (fr) 2017-05-24
PH12015501289B1 (en) 2019-02-13
JP6367822B2 (ja) 2018-08-01
UY35177A (es) 2014-06-30
US20160214977A1 (en) 2016-07-28
IL239026A0 (en) 2015-07-30
US9708311B2 (en) 2017-07-18
MY175272A (en) 2020-06-17
TN2015000250A1 (en) 2016-10-03
AR093840A1 (es) 2015-06-24
PH12015501289A1 (en) 2015-08-24
AP3862A (en) 2016-10-31
UA115576C2 (uk) 2017-11-27
CN104854098A (zh) 2015-08-19
HRP20171200T1 (hr) 2017-12-15
RS56121B1 (sr) 2017-10-31
LT2928884T (lt) 2017-08-25
NI201500077A (es) 2016-02-15
SI2928884T1 (sl) 2017-09-29
BR112015012555B1 (pt) 2022-02-15
CA2893630A1 (fr) 2014-06-12
MA38146A1 (fr) 2018-01-31
CR20150296A (es) 2015-08-10
NZ707825A (en) 2019-06-28
ES2637738T3 (es) 2017-10-16
CU20150056A7 (es) 2015-10-27
EA201591087A1 (ru) 2015-12-30
TW201422608A (zh) 2014-06-16
GT201500138A (es) 2017-10-05
KR20150092248A (ko) 2015-08-12
HK1210139A1 (en) 2016-04-15
AU2013354226B2 (en) 2017-09-14
EP2928884A1 (fr) 2015-10-14
JO3431B1 (ar) 2019-10-20
PL2928884T3 (pl) 2017-11-30

Similar Documents

Publication Publication Date Title
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2883210C (fr) Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA33299B1 (fr) Nouvelle formulation de naproxène
MA37405A1 (fr) Composés hétérocyclyle
MA32941B1 (fr) Composes organiques
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
EP2666471A4 (fr) Composition pharmaceutique pour la traitement de la rate et de l'estomac, ainsi que procédé de préparation de cette composition
WO2008152093A3 (fr) Diaminopyrimidines en tant que modulateurs du récepteur ep2
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
EP2766012A4 (fr) Compositions utiles pour le traitement d'une néphropathie et leurs procédés de préparation
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA38679B1 (fr) Modulateurs du récepteur de cxcr7